Cancer52's Manifesto 'The Other Half'

Cancer52 Annual Review for 2022-2023

Cancer52 analysis on rare and less common cancer research spend

A joint statement on the voluntary scheme for branded medicines pricing and access (VPAS)

Cancer52 Annual Review 2021-2022

Cancer52 launches inequalities report

Showcase Video

2021 All Stakeholder Briefing Report

Annual Review 2020-21

The impact of the Covid-19 pandemic on people with rare and less common cancers - Report published

Cancer52 publishes England results of its second patient survey

Health and Social Care Select Committee Report

Cancer52 publishes England results of its patient survey

Cancer52 response to Kruger review

Cancer Patients Talk About Their Care

Getting a Better Deal for Rare and Less Common Cancers - One Year on from the NHS Long Term Plan

Summary of Cancer52 / PHE Event: Development in Data for Rare and Less Common Cancers

‘Getting a better deal for people with rare and less common cancers: what we can learn from patients

A short film of patient voices

Getting a better deal for people with rare and less common cancers: the next ten years

“Clinical Nurse Specialists working with people with rare and less common cancers”

“Living with a rare or less common cancer, patient experiences of treatment and care”

“Speaking up for patients - Patient organisation involvement in Health Technology Assessment (HTA) w

“Rare and Less Common Cancers: Incidence and Mortality in England, 2010 to 2013”

New report from Cancer52: percentage of cancer deaths outside the big four rises to 54%